{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:42Z","timestamp":1790983122882,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,26]]},"DOI":"10.7759\/cureus.113394","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:05:05Z","timestamp":1785071105000},"source":"Crossref","is-referenced-by-count":1,"title":["Early-Onset Vogt-Koyanagi-Harada-Like Syndrome After Combined Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Floriane","family":"Etheve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Hainaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Riviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-022-00293-3","article-title":"Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review","volume":"12","author":"Urzua CA","year":"2022","unstructured":"Urzua CA, Herbort CP Jr, Takeuchi M, et al.. Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review. J Ophthalmic Inflamm Infect. 2022, 12:17. 10.1186\/s12348-022-00293-3","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/srep06887","article-title":"Association of HLA-DR4\/HLA-DRB1*04 with Vogt-Koyanagi-Harada disease: a systematic review and meta-analysis","volume":"4","author":"Shi T","year":"2014","unstructured":"Shi T, Lv W, Zhang L, Chen J, Chen H. Association of HLA-DR4\/HLA-DRB1*04 with Vogt-Koyanagi-Harada disease: a systematic review and meta-analysis. Sci Rep. 2014, 4:6887. 10.1038\/srep06887","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.03.036","article-title":"Classification criteria for Vogt-Koyanagi-Harada disease","volume":"228","year":"2021","unstructured":"Classification criteria for Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2021, 228.205-11. 10.1016\/j.ajo.2021.03.036","journal-title":"Am J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17071144","article-title":"Signaling pathways in melanogenesis","volume":"17","author":"D'Mello SA","year":"2016","unstructured":"D'Mello SA, Finlay GJ, Baguley BC, Askarian-Amiri ME. Signaling pathways in melanogenesis. Int J Mol Sci. 2016, 17:10.3390\/ijms17071144","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00524-0","article-title":"Vitiligo and melanoma-associated vitiligo: understanding their similarities and differences","volume":"21","author":"Cohen BE","year":"2020","unstructured":"Cohen BE, Manga P, Lin K, Elbuluk N. Vitiligo and melanoma-associated vitiligo: understanding their similarities and differences. Am J Clin Dermatol. 2020, 21:669-80. 10.1007\/s40257-020-00524-0","journal-title":"Am J Clin Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.06.004","article-title":"Outcomes of Vogt-Koyanagi-Harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies","volume":"168","author":"Shen E","year":"2016","unstructured":"Shen E, Rathinam SR, Babu M, et al.. Outcomes of Vogt-Koyanagi-Harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. Am J Ophthalmol. 2016, 168:279-86. 10.1016\/j.ajo.2016.06.004","journal-title":"Am J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-025-00484-8","article-title":"Immune checkpoint inhibitor-associated Vogt-Koyanagi-Harada-like syndrome: a descriptive systematic review","volume":"15","author":"Zhang HA","year":"2025","unstructured":"Zhang HA, Yuan AT, Chiasson N, Wu KY, Kalevar A. Immune checkpoint inhibitor-associated Vogt-Koyanagi-Harada-like syndrome: a descriptive systematic review. J Ophthalmic Inflamm Infect. 2025, 15:44. 10.1186\/s12348-025-00484-8","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14030336","article-title":"Diagnosing and managing uveitis associated with immune checkpoint inhibitors: a review","volume":"14","author":"Zhang H","year":"2024","unstructured":"Zhang H, Houadj L, Wu KY, Tran SD. Diagnosing and managing uveitis associated with immune checkpoint inhibitors: a review. Diagnostics (Basel). 2024, 14:10.3390\/diagnostics14030336","journal-title":"Diagnostics (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000001798","article-title":"Case report: ipilimumab-induced multisystem autoimmune-like toxicities suggestive of Vogt-Koyanagi-Harada-like syndrome","volume":"98","author":"Monferrer-Adsuara C","year":"2021","unstructured":"Monferrer-Adsuara C, Hern\u00e1ndez-Bel L, Hern\u00e1ndez-Garfella ML, Remol\u00ed-Sargues L, Ortiz-Salvador M, Castro-Navarro V, Cervera-Taulet E. Case report: ipilimumab-induced multisystem autoimmune-like toxicities suggestive of Vogt-Koyanagi-Harada-like syndrome. Optom Vis Sci. 2021, 98:1309-16. 10.1097\/OPX.0000000000001798","journal-title":"Optom Vis Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-020-09800-0","article-title":"Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment","volume":"142","author":"Enomoto H","year":"2021","unstructured":"Enomoto H, Kato K, Sugawara A, Itabashi M, Kondo M. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment. Doc Ophthalmol. 2021, 142:353-60. 10.1007\/s10633-020-09800-0","journal-title":"Doc Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0206","article-title":"Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma","volume":"12","author":"Gambichler T","year":"2020","unstructured":"Gambichler T, Seifert C, Lehmann M, Lukas C, Scheel C, Susok L. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Immunotherapy. 2020, 12:439-44. 10.2217\/imt-2019-0206","journal-title":"Immunotherapy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14640","article-title":"Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1\/anti-CTLA4 therapy","volume":"46","author":"Godse R","year":"2021","unstructured":"Godse R, Mcgettigan S, Schuchter LM, Ellebrecht CT, Chu EY. Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1\/anti-CTLA4 therapy. Clin Exp Dermatol. 2021, 46:1111-2. 10.1111\/ced.14640","journal-title":"Clin Exp Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14282","article-title":"Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma","volume":"45","author":"Yoshida S","year":"2020","unstructured":"Yoshida S, Shiraishi K, Mito T, Sayama K. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma. Clin Exp Dermatol. 2020, 45:908-11. 10.1111\/ced.14282","journal-title":"Clin Exp Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000933","article-title":"Uveitis associated with immune checkpoint inhibitors or BRAF\/MEK inhibitors in patients with malignant melanoma","volume":"33","author":"Sada I","year":"2023","unstructured":"Sada I, Harada Y, Hiyama T, Mizukami M, Kan T, Kawai M, Kiuchi Y. Uveitis associated with immune checkpoint inhibitors or BRAF\/MEK inhibitors in patients with malignant melanoma. Melanoma Res. 2023, 33:539-46. 10.1097\/CMR.0000000000000933","journal-title":"Melanoma Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120962044","article-title":"A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib\/trametinib therapy for advanced melanoma","volume":"32","author":"Brambati M","year":"2022","unstructured":"Brambati M, Giuffr\u00e8 C, Marchese A, Bandello F, Modorati GM, Miserocchi E. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib\/trametinib therapy for advanced melanoma. Eur J Ophthalmol. 2022, 32:NP109-13. 10.1177\/1120672120962044","journal-title":"Eur J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjae104","article-title":"VKH-like syndrome in the setting of dabrafenib and trametinib therapy for BRAF mutant metastatic melanoma: a case report","volume":"2024","author":"Gunaratnam C","year":"2024","unstructured":"Gunaratnam C, Muzicenco O, Sivagurunathan P, Franzco MH. VKH-like syndrome in the setting of dabrafenib and trametinib therapy for BRAF mutant metastatic melanoma: a case report. J Surg Case Rep. 2024, 2024:rjae104. 10.1093\/jscr\/rjae104","journal-title":"J Surg Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-03720-6","article-title":"Vogt-Koyanagi-Harada-like disease secondary to anticancer treatment: a multicentre case series","volume":"39","author":"Urzua CA","year":"2025","unstructured":"Urzua CA, Olate-Perez A, Anguita R, et al.. Vogt-Koyanagi-Harada-like disease secondary to anticancer treatment: a multicentre case series. Eye (Lond). 2025, 39:1751-7. 10.1038\/s41433-025-03720-6","journal-title":"Eye (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/518651-early-onset-vogt-koyanagi-harada-like-syndrome-after-combined-ipilimumab-and-nivolumab-for-metastatic-melanoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:05:06Z","timestamp":1785071106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/518651-early-onset-vogt-koyanagi-harada-like-syndrome-after-combined-ipilimumab-and-nivolumab-for-metastatic-melanoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.113394","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,26]]}}}